X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercebiotech.com/biotech/equlliums-lupus-candidate-delivers-new-data-teeing-opt-decision-ono
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-starts-clinical-study-to-evaluate-efficacy-of-itolizumab/articleshow/96243936.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://economictimes.indiatimes.com/industry/healthcare/biotech/biocon-biologics-says-clinical-study-for-drug-itolizumab-initiated-in-india-after-approval-from-dcgi/articleshow/88456736.cms
https://www.expresspharma.in/biocon-biologics-initiates-clinical-study-for-itolizumab-in-lupus-nephritis/
https://www.businesswire.com/news/home/20211102005311/en/Equillium-Announces-Interim-Safety-Data-and-Reduction-in-Proteinuria-for-Lupus-Patients-Treated-with-Itolizumab-in-the-EQUALISE-Study-Presented-at-the-ACR-Annual-Meeting
https://swiss.in/how-are-pharma-companies-dealing-with-challenges-posed-by-covid-19/
https://www.globenewswire.com/news-release/2020/11/06/2122020/0/en/Equillium-Announces-Positive-Interim-Data-of-Itolizumab-in-the-First-line-Treatment-of-Acute-Graft-Versus-Host-Disease.html
https://www.business-standard.com/article/companies/sales-of-biocon-s-itolizumab-surge-as-phase-4-clinical-trials-begin-120100501200_1.html
https://www.biospace.com/article/releases/equillium-presented-new-data-and-insights-on-the-cd6-alcam-pathway-in-uncontrolled-asthma-at-the-european-respiratory-society-international-congress-2020/
https://www.globenewswire.com/news-release/2020/09/15/2093713/0/en/Equillium-Announces-Successful-Completion-of-FDA-Pre-IND-Meeting-Enabling-Advancement-of-Itolizumab-into-a-Potential-Registration-Study-as-a-Treatment-for-Hospitalized-COVID-19-Pat.html
https://www.globenewswire.com/news-release/2020/08/10/2075965/0/en/Equillium-Announces-Positive-Interim-Data-with-Itolizumab-in-Acute-GVHD-Study.html#:~:text=(Nasdaq%3A%20EQ)%2C%20a,graft%2Dversus%2Dhost%20disease%20(
https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/health-ministry-decides-against-including-itolizumab-in-clinical-management-protocols-for-covid-19/articleshow/77185259.cms?from=mdr
https://www.business-standard.com/article/companies/itolizumab-to-be-a-blockbuster-opportunity-for-biocon-kiran-mazumdar-shaw-120072401632_1.html
https://www.biopharmadive.com/news/equillium-biocon-coronavirus-india-approval/581474/
https://www.expresspharma.in/covid19-updates/dcgi-approves-itolizumab-for-restricted-emergency-use-in-covid-19-treatment/
https://www.moneycontrol.com/news/india/biocon-drug-receives-dcgi-nod-for-use-in-moderate-to-severe-covid-19-patients-5536201.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-says-use-of-itolizumab-in-covid-19-treatment-encouraging/articleshow/75766590.cms
https://economictimes.indiatimes.com/industry/healthcare/biotech/biocon-extends-licensing-pact-with-equillium-for-itolizumab/articleshow/72494907.cms
http://www.globenewswire.com/news-release/2019/07/10/1880797/0/en/Equillium-Announces-Initiation-of-the-EQUIP-Phase-1b-Clinical-Trial-of-Itolizumab-for-Patients-with-Uncontrolled-Asthma.html
Market Place
Share 
